Sarepta Therapeutics, Inc.
Categories
Biopharmaceutical
About Us
THE PROMISE OF SCIENCE, REALIZED™
Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in gene therapies for 6 Limb-girdle muscular dystrophy diseases (LGMD), Charcot-Marie-Tooth (CMT), MPS IIIA, Pompe and other CNS-related disorders, totaling over 20 therapies in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is fueled by an audacious but important mission: to profoundly improve and extend the lives of patients with rare genetic-based diseases.
Images
Printed courtesy of www.cambridgechamber.org/ – Contact the Cambridge Chamber of Commerce for more information.
One Kendall Square, Cambridge, MA 02139 – (617) 876-4100 – ccinfo@cambridgechamber.org